Ireland
--:--IST
Priya Life Science Medicines register
Registers› Irish medicines ›Donepezil 5 mg film-coated tablets
Medicines register · Ireland

Donepezil 5 mg film-coated tablets

Authorisation PA2315/033/001 · Accord Healthcare Ireland Limited

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 21 Nov 2026
Licence holder
Accord Healthcare Ireland Limited (all products →)
Active substance
Donepezil hydrochloride
Clinical trials
3 clinical trials →
Dosage form
Film-coated tablet
Route of administration
Oral use
ATC codes
N06DA, N06DA02
First authorised
19/08/2011
Prescription status
Product subject to prescription which may not be renewed (A)
Supply
Supply through pharmacies only
Legal basis
Generic application (Article 10(1) of Directive No 2001/83/EC)

Donepezil hydrochloride: supply and approvals

14 authorised products on the HPRA list contain Donepezil hydrochloride. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 20 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 20 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 20 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 15 years (since 19 August 2011). The HPRA list marks it as marketed in Ireland.

Other medicines with Donepezil hydrochloride in Ireland

13 other products on the HPRA list contain Donepezil hydrochloride, from 7 licence holders; 11 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
ARICEPT 10 mg film coated tabletsPfizer Healthcare Ireland Unlimited CompanyNational authorisation (PA)Marketed
ARICEPT 5 mg film coated tabletsPfizer Healthcare Ireland Unlimited CompanyNational authorisation (PA)Marketed
Aripil 10 mg film-coated tabletsViatris LimitedNational authorisation (PA)Marketed
Aripil 5 mg film-coated tabletsViatris LimitedNational authorisation (PA)Marketed
Donepezil 10 mg film-coated tabletsAccord Healthcare Ireland LimitedNational authorisation (PA)Marketed
Donepezil Krka 10 mg film-coated tabletsKRKA, d.d., Novo mestoNational authorisation (PA)Marketed
Donepezil Krka 5 mg film-coated tabletsKRKA, d.d., Novo mestoNational authorisation (PA)Marketed
Donepezil Teva 10 mg film-coated tabletsTeva Pharma B.V.National authorisation (PA)Marketed
Donepezil Teva 5 mg film-coated tabletsTeva Pharma B.V.National authorisation (PA)Marketed
Dozept 10 mg film-coated-tabletsRowex Limited,National authorisation (PA)Marketed
Dozept 5 mg film-coated tabletsRowex Limited,National authorisation (PA)Marketed
Donepezil Hydrochloride 10mg Film-coated TabletsBrillpharma (Ireland) LimitedNational authorisation (PA)Not marketed

All 14 products with Donepezil hydrochloride →

Other substances in ATC group N06DA

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 4 other active substances share the group N06DA with this product:

Rivastigmine hydrogen tartrate (37) · Rivastigmine (6) · Galantamine (5) · Galantamine hydrobromide (1)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

Accord Healthcare Ireland Limited holds 38 products on the HPRA list, with 18 different active substances; 36 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.